Welcome to our dedicated page for Nanalysis Sci news (Ticker: NSCIF), a resource for investors and traders seeking the latest updates and insights on Nanalysis Sci stock.
Nanalysis Scientific Corp. reports developments tied to portable Nuclear Magnetic Resonance spectrometers, MRI and imaging technology, and related services for industrial and research applications. Company updates describe instruments used in pharmaceutical, biotech, energy, food, materials, security, academic, and government settings, as well as a services division that maintains Nanalysis products and third-party imaging equipment.
Recurring news themes include quarterly and annual results, conference-call announcements, supply-chain and market-diversification updates, non-dilutive funding, private placement financings, equity incentive grants, and board composition changes. The company also references its long-term Canadian Air Transport Security Authority relationship for security-scanner maintenance at Canadian airports.
Nanalysis (OTC:NSCIF) reported Q1 2026 revenue of $10.7 million, up 1% year over year, and Adjusted EBITDA of $292 thousand, up from $180 thousand. Net loss narrowed slightly to $1.28 million.
Product sales fell 41%, while security services revenue rose 18% and service margins improved to 19%. The company repaid about $3.4 million of ATB debt and continued cost-optimization and European sales expansion initiatives.
Nanalysis Scientific (OTC:NSCIF) will release its first quarter 2026 results after market close on Wednesday, May 20, 2026. Management will host a conference call at 10:00 a.m. ET on Thursday, May 21, 2026 to discuss the results.
The live event will be accessible via Zoom, and an archived webcast will be available on the company’s investor relations webpage for at least 90 days, allowing investors to review the discussion on demand.
Nanalysis (OTC: NSCIF) announced board changes effective May 1, 2026: Jonathan Ladd, Werner Maas, and Steve Feick were appointed to the board, while Martin Burian and Jennifer Stubbs stepped down. The appointments add experience in portable NMR/MRI instrumentation, global commercialization, and capital allocation to support scaling and services growth.
Nanalysis (OTC: NSCIF) reported Q4 2025 revenue of $10.7 million (down 13% YoY) and full-year revenue of $40.1 million (down 12% YoY). Q4 adjusted EBITDA returned to positive at $1.2 million; full-year adjusted EBITDA was $0.9 million. Product sales fell, services grew 5% for the year, and product gross margin improved to 57% for 2025.
Management cited supply‑chain diversification, cost reductions, a $3.4M private placement, $1.0M non‑dilutive funding, and signed distribution and associate contracts as strategic actions to stabilize operations and improve 2026 performance.
Nanalysis (TSXV: NSCI / OTC: NSCIF) will release fourth quarter and full year 2025 results after market close on Wednesday, April 8, 2026. CEO Sean Krakiwsky and Interim CFO Heather Kury will host a conference call at 10:00 AM ET on Thursday, April 9, 2026.
Investors can join via Zoom (meeting ID and passcode provided) and a webcast archive will be available on the company investor relations webpage for at least 90 days.
Nanalysis (OTC: NSCIF) announced on March 4, 2026 that its Board granted 1,210,000 restricted share units (RSUs) and 350,000 stock options to certain directors, officers and employees under its equity plans. Each option is exercisable for one common share at $0.20 per share for five years. Each vested RSU entitles the holder to one common share.
Nanalysis (OTCQX: NSCIF, TSXV: NSCI) closed the second and final tranche of its $3.4 million non‑brokered private placement on Jan 26, 2026. The Second Tranche issued 6,145,300 units at $0.15 per unit for gross proceeds of $921,795, bringing the Offering total to 22,671,583 units. Each unit includes one share and one‑half warrant; each whole warrant allows purchase of one share at $0.20 until two years from closing, subject to acceleration if the share price trades at $0.30 for 10 consecutive trading days. The company paid $2,000 in finder’s fees to Leede Financial and securities remain subject to a statutory hold period of four months plus one day. TSX Venture final acceptance is pending.
Nanalysis (OTCQX: NSCIF) closed the first tranche of a non‑brokered private placement on Dec 23, 2025, issuing 16,526,283 Units at $0.15 each for gross proceeds of about $2.5M. Each Unit includes one share and one‑half warrant; each full warrant is exercisable at $0.20 until two years from closing with acceleration if the share price trades at $0.30 for 10 consecutive days. The company upsized the Offering to allow issuance of up to an additional 23,333,333 Units for up to $3.5M, subject to TSX Venture Exchange approval. Net proceeds are earmarked for debt reduction and magnet inventory purchases; securities issued carry a statutory four‑month plus one‑day hold.
Nanalysis (OTCQX: NSCIF) announced a non-brokered private placement of up to 16,666,667 Units at $0.15 per Unit to raise up to $2,500,000 in gross proceeds. Each Unit comprises one common share and one-half of one warrant; the 8,333,333 whole Warrants will be exercisable at $0.20 per share until two years from closing and include an acceleration clause if the share price trades at $0.30 for 10 consecutive trading days. Net proceeds are designated for debt reduction. Closing is subject to TSX Venture Exchange acceptance, may occur in tranches, and an initial close is anticipated on or about December 15, 2025. Securities will carry a statutory hold period of four months and one day.
Nanalysis Scientific Corp. (OTCQX: NSCIF) reported Q3 2025 consolidated revenue of $9,285K, down 12% year-over-year, and nine-month revenue of $29,455K, down 11% year-over-year. Product sales declined sharply: $2,719K in Q3 (-36% YoY) and $9,308K YTD (-33% YoY). Security services revenue grew: Q3 $5,943K (+10% YoY) and YTD $16,583K (+8% YoY). Q3 product gross margin fell to 44% from 52%, while nine-month product margin improved to 58% from 50%. Adjusted EBITDA was ($2K) for Q3 and ($284K) YTD. Net loss improved to ($1,500K) in Q3 and ($4,929K) YTD. The company executed a five-year OEM and licensing agreement with IMRIS, resolved magnet supply constraints, and is restructuring its sales organization to refocus on benchtop NMR sales.